cGMP and Peptide Manufacturing: Supplier Evidence to Review
Evaluate manufacturing claims with facility identity, quality-system evidence, inspection context, and lot records rather than relying on a cGMP marketing badge.
For facility-specific purchasing requirements, visit our medical clinics sourcing guide. This article covers procurement, not treatment protocols.
A marketing phrase is not the evidence
Current good manufacturing practice refers to manufacturing quality requirements and controls. A statement that a company is “cGMP aligned” is not, on its own, proof of compliance or FDA approval of a product. Ask which facility and activities the claim concerns.
Identify who performed each step
Determine who manufactured, compounded, tested, packaged, stored, and shipped the preparation. A seller may not perform those activities itself. Record the responsible entities so questions about a batch reach the right quality team.
Review public and supplied records together
Verify registration and relevant licensing, review available inspection and enforcement information in context, and request the supplier’s explanation of unresolved concerns. Absence of a public action is not proof that every batch meets requirements.
Ask how changes and complaints are controlled
Request evidence of processes for material qualification, deviations, changes, complaints, and recalls. A quality-system overview can support qualification, but the actual lot still needs applicable documentation and receiving checks.
Reassess when the source changes
A new manufacturing site, testing arrangement, or formulation should trigger review rather than inheriting an old approval automatically. Retain the source evidence and decision date in the clinic’s supplier file.
What to do next
Record unresolved questions and the evidence your clinical or quality reviewer needs before ordering. Use the medical clinics purchasing page to prepare a facility-specific inquiry. Product mentions do not confirm stock, a legal supply pathway, or suitability for patient care.
Regulatory sources and purchasing limits
Compounded drugs are not FDA-approved. Facility registration does not establish approval or eligibility for every preparation. Verify the exact product, source, applicable federal requirements, and state rules before ordering. This is procurement education, not medical or legal advice.
- FDA: bulk substances used under section 503B, including restrictions and interim policies.
- FDA: GLP-1 compounding and shortage updates.
- FDA: safety concerns for certain compounding substances.